Tokyo: Daiichi Sankyo has announced that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for an omicron XBB.1.5-adapted mRNA.
Tokyo: Daiichi Sankyo has announced that ENHERTU (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with unresectable advanced or recurrent non-small cell lung.
Tokyo: Daiichi Sankyo has announced that it has decided to close its Japanese research and development (R&D) subsidiary, Daiichi Sankyo RD Novare Co., Ltd. (headquartered in Edogawa-ku, Tokyo;.
DAICHIRONA for Intramuscular Injection is an mRNA vaccine against COVID-19 designed to produce antibodies against the receptor binding domain of the spike protein of the novel coronavirus, utilizing a.
Adult T-cell leukemia-lymphoma (abbreviated ATLL or ATL) is a rare and aggressive hematologic malignancy that is caused by human T-cell lymphotropic virus type 1 (HTLV-1).